Free tool
FAERS Monitor: Ocrevus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761053 or its brand name (Ocrevus, Ocrelizumab). Reports on generic versions are filed under their own applications.
Reports
62,729
Serious
31,724
51% of reports
Hospitalization
11,416
Death reported
1,540
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- covid-1911,587
- fatigue6,297
- urinary tract infection3,818
- headache3,311
- multiple sclerosis3,123
- multiple sclerosis relapse2,818
- gait disturbance2,756
- asthenia2,735
- nasopharyngitis2,601
- pain2,585
- fall2,559
- drug ineffective2,491
- off label use2,488
- pneumonia2,472
- infusion related reaction2,247
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 17 |
| 2013 | 7 |
| 2014 | 12 |
| 2015 | 10 |
| 2016 | 30 |
| 2017 | 1,129 |
| 2018 | 4,995 |
| 2019 | 6,275 |
| 2020 | 5,549 |
| 2021 | 7,193 |
| 2022 | 11,405 |
| 2023 | 8,927 |
| 2024 | 9,566 |
| 2025 | 4,551 |
| 2026 | 3,037 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,991,430 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| covid-19Signal | 11,587 | 23.6 | 23.2 | 236,586 |
| multiple sclerosisSignal | 3,123 | 23.4 | 22.5 | 62,596 |
| multiple sclerosis relapseSignal | 2,818 | 14.3 | 13.8 | 33,615 |
| infusion related reactionSignal | 2,247 | 11.7 | 11.3 | 21,364 |
| urinary tract infectionSignal | 3,818 | 7.7 | 7.4 | 21,761 |
| gait disturbanceSignal | 2,756 | 4.9 | 4.7 | 8,463 |
| nasopharyngitisSignal | 2,601 | 4.8 | 4.6 | 7,740 |
| fatigueSignal | 6,297 | 2.7 | 2.7 | 7,086 |
| fallSignal | 2,559 | 2.6 | 2.5 | 2,517 |
| pneumoniaSignal | 2,472 | 2.6 | 2.5 | 2,392 |
| astheniaSignal | 2,735 | 2.4 | 2.4 | 2,370 |
| headache | 3,311 | 1.8 | 1.7 | 1,147 |
| pain | 2,585 | 1.4 | 1.4 | 319 |
| off label use | 2,488 | 1.0 | 0.9 | 6 |
| drug ineffective | 2,491 | 0.6 | 0.6 | 564 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.